|
Summary
January 2007, Vol. 16, No. 1, Pages 1-10
, DOI 10.1517/13543784.16.1.1
Discontinued drugs in 2005: anti-infectivesNafsika GeorgopapadakouMethylGene, Inc., 7220 Frederick-Banting, Montreal, QC H4S 2A1, Canada. nafsikag@aol.com This perspective is the fifth in a series discussing drugs dropped from development in 2005, of which 11 were being developed for infectious diseases. Of these, eight were antivirals and were dropped in Phase II or III: Medivir's alovudine, Ono Pharmaceuticals' aplaviroc hydrochloride and Excite's immunotherapeutic Xcellerate™ for HIV; Boehringer Ingelheim's ciluprevir, ViroPharma's HCV-086, Isis Pharmaceuticals' antisense oligonucleotide ISIS-14803, Japan Tobacco's JTK-003 and Rigel's R803 for hepatitis C virus. The remaining discontinued anti-infective drugs were an antibacterial vaccine (Vical's anthrax vaccine), an antiseptic (YM Bioscience's Dermofural™) and an antifungal formulation (MacroChem's topical econazole). The drugs are grouped by compound class and reasons for their failure are discussed in this article. Forward Links to Citing ArticlesLiesbeth Lenaerts, Erik De Clercq, Lieve Naesens. (2008) Clinical features and treatment of adenovirus infections. Reviews in Medical Virology 18:6, 357-374 Online publication date: 1-Dec-2008. CrossRef Andrew P Rice, Richard E Sutton. (2007) Targeting protein–protein interactions for HIV therapeutics. Future HIV Therapy 1:4, 369-385 Online publication date: 1-Dec-2007. CrossRef |
|





TOC Alert